GeoVax Labs Implements 1-for-25 Reverse Stock Split
GOVX filed a Corporate Governance and Compliance on light trading volume (0.2× avg).
Summary
GeoVax Labs, Inc. has implemented a 1-for-25 reverse stock split, effective January 9, 2026, to increase its per-share price.
Key Events · Corporate Governance and Compliance · GOVX
-
Reverse Stock Split Implemented
GeoVax Labs, Inc. filed a Certificate of Amendment to its Certificate of Incorporation to effect a 1-for-25 reverse stock split.
-
Effective Date
The reverse stock split became effective on January 9, 2026.
-
Fractional Shares Handled
No fractional shares will be issued; instead, they will be rounded up to the nearest whole share.
-
Ownership Unchanged
Each stockholder's percentage ownership interest and proportional voting power remain substantially unchanged, aside from minor adjustments due to rounding.
Analysis · GOVX · Life Sciences
The 1-for-25 reverse stock split is a significant corporate action typically undertaken by companies to raise their per-share price, often to meet exchange listing requirements. While this action does not change the company's overall market capitalization or a shareholder's proportional ownership, it frequently signals underlying challenges or a need to improve stock perception. The rounding up of fractional shares is a minor benefit for affected shareholders. Investors should monitor the company's stock performance and future operational updates to understand the long-term implications of this action.
How filings like this one have moved
In the 30 days to Oct 31, 2026, 39.9% of the 1148 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, GOVX was trading at $3.64 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $179.3M. The 52-week trading range was $0.12 to $4.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.